<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842333</url>
  </required_header>
  <id_info>
    <org_study_id>P/2015/263</org_study_id>
    <nct_id>NCT02842333</nct_id>
  </id_info>
  <brief_title>Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor</brief_title>
  <acronym>PAMIR01</acronym>
  <official_title>Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators recently identified promiscuous HLA-DR-derived epitopes from the human
      telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study
      tumor-specific CD4+ T cell responses.

      The aim of this prospective preliminary study is to evaluate the presence of UCP-specific Th1
      responses in patients in complete remission of CML two years after end of Tyrosine Kinase
      Inhibitor (TKi) treatments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UCP-specific Th1 responses measured by ELISPOT assay</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Leukemia</condition>
  <arm_group>
    <arm_group_label>Additional biological samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be realized at inclusion and 6 months after inclusion (optional).
Peripheral Blood Mononuclear Cells (PBMC) will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional biological samples</intervention_name>
    <description>Blood samples</description>
    <arm_group_label>Additional biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For cohort A :

               -  patient with chronic myelogenous leukemia in chronic phase in deep molecular
                  response (MR4.0) persistent for 2 years or more after end of TKi treatments

               -  patient with total cessation of TKi treatment

               -  signed written informed consent

          -  For cohort B :

               -  patient with chronic myelogenous leukemia in chronic phase, for whom a diagnosis
                  of relapse was increased 1 year or less after stopping treatment with TKIs
                  (inclusion of patient under TKi treatment after relapse is possible).

               -  signed written informed consent

        Exclusion Criteria (for all patients) :

          -  patients under chronic treatment with systemic corticoids or other immunosuppressive
             drugs (corticoids ≤ 10 mg/day is allowed)

          -  active autoimmune diseases, HIV, hepatitis C or B virus

          -  patient with any medical or psychiatric condition or disease which would make the
             patient inappropriate for entry into this study.

          -  patient under guardianship, curator or under the protection of justice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabrice LAROSA, Dr</last_name>
    <email>flarosa@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe BORG, Pr</last_name>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice LAROSA, Dr</last_name>
      <email>flarosa@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice LAROSA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis CAILLOT, Dr</last_name>
      <email>denis.caillot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Denis CAILLOT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence LEGROS, Dr</last_name>
      <email>Legros.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence LEGROS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine REA, Dr</last_name>
      <email>delphine.rea@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Delphine REA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

